ONKURE THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
ONKURE THERAPEUTICS, INC. (OKUR) reported Payments to Acquire Debt Securities, Available-for-sale of $67.75 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2024-11-07
- ONKURE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ONKURE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-06-30 was $22.51M, a 78.36% decline year-over-year.
- ONKURE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-03-31 was $45.24M, a 59.75% increase year-over-year.
- ONKURE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-12-31 was $41.20M, a 20.23% increase year-over-year.
- ONKURE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $231.26M, a 127.62% increase from fiscal 2022.
- ONKURE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $101.60M, a 223.49% increase from fiscal 2021.
- ONKURE THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $31.41M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $22.51M derived: sum of 2 quarters · filed 2024-11-07 | $67.75M 10-Q · filed 2024-11-07 | $108.95M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $22.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $67.75M 10-Q · filed 2024-08-13 | $108.95M derived: sum of 3 quarters · filed 2024-08-13 | $166.68M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $45.24M 10-Q · filed 2024-05-07 | $86.44M derived: sum of 2 quarters · filed 2024-05-07 | $144.17M derived: sum of 3 quarters · filed 2024-11-07 | $248.18M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $41.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $98.93M derived: sum of 2 quarters · filed 2024-11-07 | $202.94M derived: sum of 3 quarters · filed 2024-11-07 | $231.26M 10-K · filed 2024-03-28 |
| 2023-09-30 | $57.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $161.74M derived: sum of 2 quarters · filed 2024-11-07 | $190.06M 10-Q · filed 2024-11-07 | $224.32M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $104.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $132.33M 10-Q · filed 2024-08-13 | $166.59M derived: sum of 3 quarters · filed 2024-08-13 | $218.00M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $28.32M 10-Q · filed 2024-05-07 | $62.59M derived: sum of 2 quarters · filed 2024-05-07 | $114.00M derived: sum of 3 quarters · filed 2024-05-07 | $113.89M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $34.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $85.67M derived: sum of 2 quarters · filed 2024-03-28 | $85.57M derived: sum of 3 quarters · filed 2024-03-28 | $101.60M 10-K · filed 2024-03-28 |
| 2022-09-30 | $51.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $51.30M derived: sum of 2 quarters · filed 2023-11-13 | $67.33M 10-Q · filed 2023-11-13 | $67.31M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$107.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $15.92M 10-Q · filed 2023-08-10 | $15.91M derived: sum of 3 quarters · filed 2023-08-10 | $20.34M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $16.03M 10-Q · filed 2023-05-11 | $16.01M derived: sum of 2 quarters · filed 2023-05-11 | $20.45M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $4.42M derived: sum of 2 quarters · filed 2023-03-27 | $31.41M 10-K · filed 2023-03-27 | |
| 2021-09-30 | $4.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $31.42M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $26.99M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |